Daily Stock Analysis, BAX, Baxter International Inc, priceseries

Baxter International Inc. Daily Stock Analysis
Stock Information
Open
60.68
Close
61.38
High
61.51
Low
60.45
Previous Close
60.68
Daily Price Gain
0.70
YTD High
61.51
YTD High Date
Jun 23, 2017
YTD Low
43.95
YTD Low Date
Jan 3, 2017
YTD Price Change
17.05
YTD Gain
38.47%
52 Week High
61.51
52 Week High Date
Jun 23, 2017
52 Week Low
41.87
52 Week Low Date
Jun 27, 2016
52 Week Price Change
17.89
52 Week Gain
41.14%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jul 28. 2015
37.33
Aug 12. 2015
39.76
11 Trading Days
6.53%
Link
LONG
Oct 15. 2015
33.13
Nov 12. 2015
36.91
20 Trading Days
11.42%
Link
LONG
Apr 12. 2016
41.56
May 17. 2016
44.44
25 Trading Days
6.93%
Link
LONG
Jan 31. 2017
47.79
Mar 16. 2017
51.21
31 Trading Days
7.17%
Link
Company Information
Stock Symbol
BAX
Exchange
NYSE
Company URL
http://www.baxter.com
Company Phone
8479482000
CEO
Joe Almeida
Headquarters
Business Address
ONE BAXTER PKWY, DF2-1W, DEERFIELD, IL 60015
Sector
Equity
Industry Category
Industry Group
CIK
About

Baxter International, Inc. provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. Its products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctor's offices and by patients at home under physician supervision. It operates through the following segments: Hospital Products and Renal. The Hospital Products segment intravenous IV solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, inhalation anesthetics, and biosurgery products. This segment also provides products and services related to pharmacy compounding, drug formulation. The Renal segment provides products and services to treat end-stage renal disease, or irreversible kidney failure and acute kidney injuries. This segment offers a comprehensive portfolio to meet the needs of patients across the treatment continuum, including technologies and therapies for peritoneal dialysis, in-center hemodialysis, home HD, continuous renal replacement therapy and additional dialysis services. Baxter International was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Description

Baxter International Inc. provides a portfolio of renal and hospital products. The company operates through two segments, Hospital Products and Renal. The Hospital Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics, and biosurgery products. This segment also provides products and services related to pharmacy compounding, drug formulation, and packaging technologies. The Renal segment provides products to treat end-stage renal disease, irreversible kidney failure, and acute kidney therapies. This segment offers products for various treatment continuums, such as technologies and therapies for peritoneal dialysis, hemodialysis, continuous renal replacement therapy, and additional dialysis services. The company sells its products for use in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and by patients at home under physician supervision. It offers its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. The company has a collaboration agreement with JW Holdings Corporation to co-develop and distribute parenteral nutritional products containing a novel formulation of omega 3 lipids; and agreement with Celerity Pharmaceutical, LLC to develop certain acute care generic injectable premix and oncolytic molecules. It also has a strategic partnership with ScinoPharm Taiwan, Ltd. to develop, manufacture, and commercialize five injectable drugs for cancer treatments, such as lung cancer, multiple myeloma, and breast cancer, as well as medication to treat nausea and vomiting, and side effects of chemotherapy. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.